Abstract
Microtubule-Targeting Agents (MTAs) constitute a class of drugs largely used in cancer treatment. Among them, both taxanes and Vinca-alkaloids are known to inhibit cancer cell proliferation by inducing cell cycle arrest and subsequent apoptosis. These agents modify the cytoskeleton by affecting the tubulin/microtubule system. In cancer cells, both classes suppress microtubule dynamics through inhibition of microtubule dynamic instability and treadmilling, and commonly induce diverse signals responsible for cell death initiation and execution via the mitochondrial intrinsic pathway. However, links between microtubule network disturbance and the involvement of mitochondria in apoptosis are not obvious, and one may think that they could be independent. Nevertheless, several intracellular proteins could connect microtubules and the apoptotic machinery. The aim of the present review is to provide elements that could answer to the question : is microtubule disruption dispensable for MTA-induced apoptosis? The first section is focused on the mechanisms responsible for the MTA-mediated apoptosis. Then, links between cell cycle regulators and apoptosis are underlined since MTA induce cell cycle arrest by inhibiting microtubules. In the third part, the potential involvement of microtubule-sequestered and/or -transported proteins in apoptotic signalisation is discussed. Lastly, the possible role of the tubulin/microtubule system in direct effects of MTAs on mitochondria is summarized. Thus, it becomes clear that microtubule network and apoptosis are deeply linked in MTA effectiveness, through a cascade of cellular events. It could lead to identification of new biomarkers of MTA effectiveness, that could improve combinatorial therapy with MTAs and provide crucial arms to circumvent resistance of cancer cells.
Keywords: permeability transition pore, Mitochondria, p38MAPK, spindle checkpoint, Bcl-2 Proteins
Current Cancer Drug Targets
Title: Microtubules in Apoptosis Induction: Are They Necessary?
Volume: 7 Issue: 8
Author(s): D. Braguer, M. Carre and M.-A. Esteve
Affiliation:
Keywords: permeability transition pore, Mitochondria, p38MAPK, spindle checkpoint, Bcl-2 Proteins
Abstract: Microtubule-Targeting Agents (MTAs) constitute a class of drugs largely used in cancer treatment. Among them, both taxanes and Vinca-alkaloids are known to inhibit cancer cell proliferation by inducing cell cycle arrest and subsequent apoptosis. These agents modify the cytoskeleton by affecting the tubulin/microtubule system. In cancer cells, both classes suppress microtubule dynamics through inhibition of microtubule dynamic instability and treadmilling, and commonly induce diverse signals responsible for cell death initiation and execution via the mitochondrial intrinsic pathway. However, links between microtubule network disturbance and the involvement of mitochondria in apoptosis are not obvious, and one may think that they could be independent. Nevertheless, several intracellular proteins could connect microtubules and the apoptotic machinery. The aim of the present review is to provide elements that could answer to the question : is microtubule disruption dispensable for MTA-induced apoptosis? The first section is focused on the mechanisms responsible for the MTA-mediated apoptosis. Then, links between cell cycle regulators and apoptosis are underlined since MTA induce cell cycle arrest by inhibiting microtubules. In the third part, the potential involvement of microtubule-sequestered and/or -transported proteins in apoptotic signalisation is discussed. Lastly, the possible role of the tubulin/microtubule system in direct effects of MTAs on mitochondria is summarized. Thus, it becomes clear that microtubule network and apoptosis are deeply linked in MTA effectiveness, through a cascade of cellular events. It could lead to identification of new biomarkers of MTA effectiveness, that could improve combinatorial therapy with MTAs and provide crucial arms to circumvent resistance of cancer cells.
Export Options
About this article
Cite this article as:
Braguer D., Carre M. and Esteve M.-A., Microtubules in Apoptosis Induction: Are They Necessary?, Current Cancer Drug Targets 2007; 7 (8) . https://dx.doi.org/10.2174/156800907783220480
DOI https://dx.doi.org/10.2174/156800907783220480 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dual Roles of Sulforaphane in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Recent Patents in Circulating Cell-Free Tumor DNA as Biomarker in Cancer
Recent Patents on Biomarkers Anticancer Drugs in Liposomal Nanodevices: A Target Delivery for a Targeted Therapy
Current Topics in Medicinal Chemistry Inhibitors of Chronically Active Ras: Potential for Treatment of Human Malignancies
Recent Patents on Anti-Cancer Drug Discovery Therapeutic Potential of Multifunctional Tacrine Analogues
Current Neuropharmacology Overcoming Cell Death and Tau Phosphorylation Mediated by PI3KInhibition: A Cell Assay to Measure Neuroprotection
CNS & Neurological Disorders - Drug Targets Synthesis of New Galanthamine-Peptide Derivatives Designed for Prevention and Treatment of Alzheimer’s Disease
Current Alzheimer Research Understanding the Role of Poloxamer 407 based Thermoreversible In Situ Gelling Hydrogel for Delivery of PEGylated Melphalan Conjugate
Current Drug Delivery Individualized Treatment Planning in Oncology: Role of PET and Radiolabelled Anticancer Drugs in Predicting Tumour Resistance
Current Pharmaceutical Design Possibility of Non-Immunosuppressive Immunophilin Ligands as Potential Therapeutic Agents for Parkinsons Disease
Current Pharmaceutical Design Identifying Molecular Targets Mediating the Anticancer Activity of Histone Deacetylase Inhibitors: A Work in Progress
Current Cancer Drug Targets Alzheimer’s Disease and Molecular Chaperones: Current Knowledge and the Future of Chaperonotherapy
Current Pharmaceutical Design Recent Advances in the Molecular Pathogenesis of Dystonia-Plus Syndromes and Heredodegenerative Dystonias
Current Neuropharmacology Organ Preference of Cancer Metastasis and Metastasis-Related Cell Adhesion Molecules Including Carbohydrates
Cardiovascular & Hematological Disorders-Drug Targets Synthetic and Biological Vesicular Nano-Carriers Designed for Gene Delivery
Current Pharmaceutical Design The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of Bortezomib
Current Pharmaceutical Design Mitophagy and Disease: New Avenues for Pharmacological Intervention
Current Pharmaceutical Design Potential Roles of Selenium and Selenoproteins in the Prevention of Alzheimer's Disease
Current Topics in Medicinal Chemistry Targets for Anti-metastatic Drug Development
Current Pharmaceutical Design Small Players With Big Roles: MicroRNAs as Targets to Inhibit Breast Cancer Progression
Current Drug Targets